Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Adipose tissue-derived mesenchymal stem cells combined with prednisone synergistically ameliorate autoimmune hepatitis in mice.

Kong J., Liang X., Chen G., Liu X., Liao N., Li D.

Animal Study on Autoimmune Research, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42163288
DOI
10.1186/s13287-026-05069-3

Abstract (original English)

Background The combination of adipose tissue-derived mesenchymal stem cell (ADSC) transplantation with conventional therapy for autoimmune hepatitis (AIH) represents a critical step toward the clinical translation of ADSC-based therapeutics. However, no preclinical studies have yet reported on such combination therapy for AIH. This study aims to evaluate the therapeutic efficacy of ADSC-prednisone (AP) combined therapy in an AIH mouse model and to investigate the underlying mechanisms. Methods ConA-induced and CFA/S100-induced AIH mice were treated with prednisone, ADSCs, or AP combination therapy. Serum biochemistry, histopathology, immune cell infiltration, cytokine profiles, MAPK signaling pathways (p38/MAPK, JNK/ERK), and single-cell RNA sequencing (scRNA-seq) were analyzed. Results Both ADSC and prednisone monotherapies significantly reduced serum transaminases (ALT, AST, ALP, TBIL) and hepatic inflammation compared with untreated controls. Notably, AP combination therapy demonstrated superior protection, with greater reductions in immune cell infiltration (CD4⁺, CD8⁺, CD11b⁺), pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-12), and autoantibody production (IgG). Mechanistically, ADSCs suppressed p38/MAPK activation, while AP further enhanced inhibition of JNK/p38 signaling. scRNA-seq revealed that AP therapy reshaped the liver cellular landscape, reduced immune cell a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHepatitis, AutoimmuneMiceMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPrednisoneAdipose TissueDisease Models, AnimalCytokines

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research